A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer

被引:1
|
作者
Bolton, Katherine A. [1 ,2 ]
Avery-Kiejda, Kelly A. [1 ,2 ]
Holliday, Elizabeth G. [3 ,4 ]
Attia, John [3 ,4 ]
Bowden, Nikola A. [1 ,2 ]
Scott, Rodney J. [1 ,2 ,5 ,6 ]
机构
[1] Hunter Med Res Inst, Ctr Bioinformat Biomarker Discovery & Informat Ba, Newcastle, NSW, Australia
[2] Univ Newcastle, Fac Hlth & Med, Sch Biomed Sci & Pharm, Prior Res Ctr Canc, Newcastle, NSW, Australia
[3] Univ Newcastle, Fac Hlth & Med, Sch Med & Publ Hlth, Ctr Clin Epidemiol & Biostat, Newcastle, NSW, Australia
[4] Hunter Med Res Inst, Clin Res Design IT & Stat Support Unit, Newcastle, NSW, Australia
[5] John Hunter Hosp, Pathol North, Mol Med, Newcastle, NSW, Australia
[6] Univ Newcastle, Fac Hlth & Med, Sch Biomed Sci & Pharm, Discipline Med Genet, Univ Dr, Newcastle, NSW, Australia
基金
英国医学研究理事会;
关键词
IGF1; gene; short tandem repeat; promoter region; endometrial cancer; breast cancer; GROWTH-FACTOR-I; FACTOR-RECEPTOR GENE; BODY-MASS INDEX; BREAST-CANCER; CA REPEAT; SEQUENCE REPEAT; TANDEM REPEATS; OBESITY; DNA; SUSCEPTIBILITY;
D O I
10.1530/EC-16-0003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Due to the lack of high-throughput genetic assays for tandem repeats, there is a paucity of knowledge about the role they may play in disease. A polymorphic CA repeat in the promoter region of the insulin-like growth factor 1 gene (IGF1) has been studied extensively over the past 10 years for association with the risk of developing breast cancer, among other cancers, with variable results. The aim of this study was to determine if this CA repeat is associated with the risk of developing breast cancer and endometrial cancer. Using a case-control design, we analysed the length of this CA repeat in a series of breast cancer and endometrial cancer cases and compared this with a control population. Our results showed an association when both alleles were considered in breast and endometrial cancers (P = 0.029 and 0.011, respectively), but this did not pass our corrected threshold for significance due to multiple testing. When the allele lengths were analysed categorically against the most common allele length of 19 CA repeats, an association was observed with the risk of endometrial cancer due to a reduction in the number of long alleles (P = 0.013). This was confirmed in an analysis of the long alleles separately for endometrial cancer risk (P = 0.0012). Our study found no association between the length of this polymorphic CA repeat and breast cancer risk. The significant association observed between the CA repeat length and the risk of developing endometrial cancer has not been previously reported.
引用
收藏
页码:115 / 122
页数:8
相关论文
共 50 条
  • [1] Association between CA repeat polymorphism in IGF1 gene promoter and colorectal cancer risk in a native Chinese population
    Chao, X. L.
    Wang, L. L.
    Liu, R.
    Li, Y.
    Zhou, X. J.
    [J]. NEOPLASMA, 2019, 66 (06) : 1002 - 1008
  • [2] An association between polymorphism in CA repeat in 5′ promoter region of IGF 1 and risk of endometrial cancer development
    Kwasniewski, Wojciech
    Gozdzicka-Jozefiak, Anna
    Wolun-Cholewac, Maria
    Sierocinska-Sawa, Jadwiga
    Kotarska, Maria
    Kotarski, Jan
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2015, 36 : S16 - S16
  • [3] The association between IGF1 CA repeat polymorphisms and breast cancer risk: a meta-analysis
    Huang, Qiang
    Wang, Cheng
    Qiu, Lu-Jun
    Shao, Feng
    Yu, Ji-Hai
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 129 (01) : 191 - 194
  • [4] The association between IGF1 CA repeat polymorphisms and breast cancer risk: a meta-analysis
    Qiang Huang
    Cheng Wang
    Lu-Jun Qiu
    Feng Shao
    Ji-Hai Yu
    [J]. Breast Cancer Research and Treatment, 2011, 129 : 191 - 194
  • [5] The IGF1 P2 promoter is an epigenetic QTL for circulating IGF1 and human growth
    Ouni, Meriem
    Gunes, Yasemin
    Belot, Marie-Pierre
    Castell, Anne-Laure
    Fradin, Delphine
    Bougneres, Pierre
    [J]. CLINICAL EPIGENETICS, 2015, 7 : 2 - 12
  • [6] Haplotype effect in the IGF1 promoter accounts for the association between microsatellite and serum IGF1 concentration
    Chen, Holly Y.
    Chan, Iris H. S.
    Sham, Aprille L. K.
    Leung, Vincent H. K.
    Ma, Suk L.
    Ho, Suzanne C.
    Tang, Nelson L. S.
    [J]. CLINICAL ENDOCRINOLOGY, 2011, 74 (04) : 520 - 527
  • [7] The IGF1 P2 promoter is an epigenetic QTL for circulating IGF1 and human growth
    Meriem Ouni
    Yasemin Gunes
    Marie-Pierre Belot
    Anne-Laure Castell
    Delphine Fradin
    Pierre Bougnères
    [J]. Clinical Epigenetics, 2015, 7
  • [8] Polymorphisms in IGF1 associated with an increased risk of prostate cancer
    Pippa Murdie
    [J]. Nature Clinical Practice Urology, 2006, 3 (4): : 183 - 183
  • [9] IGF1 and risk of additional breast cancer in the WHEL study
    Al-Delaimy, Wael K.
    Flatt, Shirley W.
    Natarajan, Loki
    Laughlin, Gail A.
    Rock, Cheryl L.
    Gold, Ellen B.
    Caan, Bette J.
    Parker, Barbara A.
    Pierce, John P.
    [J]. ENDOCRINE-RELATED CANCER, 2011, 18 (02) : 235 - 244
  • [10] Growth hormone and IGF1 concentrations affect cancer risk
    Thomas, L
    [J]. LANCET ONCOLOGY, 2005, 6 (07): : 448 - 448